{"transactions":[{"id":1046261,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Performance Restricted Stock Unit (PRSU)","published_at":"2025-09-08T20:54:43.000Z","date":"2025-09-04","kind":"exercise","planned":false,"acquired":false,"shares":455000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Represents PRSUs previously reported on January 14, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones."}],"balance_after":0,"derivative":{"expiration_date":"2029-01-13","underlying":"Common Stock","underlying_shares":455000},"source":{"system":"sec-edgar","filing":"0000950170-25-113591","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/949858/000095017025113591/ownership.xml","form_type":"4"}},{"id":1046260,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-08T20:54:43.000Z","date":"2025-09-04","kind":"sale","planned":false,"acquired":false,"shares":139858,"price":2.77,"value":387406.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":315142,"source":{"system":"sec-edgar","filing":"0000950170-25-113591","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/949858/000095017025113591/ownership.xml","form_type":"4"}},{"id":1046259,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-08T20:54:43.000Z","date":"2025-09-04","kind":"exercise","planned":false,"acquired":true,"shares":455000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock acquired upon settlement of the performance restricted stock units (\"PRSUs\") listed in Table II."}],"balance_after":455000,"source":{"system":"sec-edgar","filing":"0000950170-25-113591","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000095017025113591/ownership.xml","form_type":"4"}},{"id":1116873,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-10T20:48:51.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders."}],"balance_after":31500,"derivative":{"exercise_price":3.83,"expiration_date":"2035-06-06","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0000950170-25-084415","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000095017025084415/ownership.xml","form_type":"4"}},{"id":1303879,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T21:42:01.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 1/4 of the total award on the first anniversary of August 26, 2024, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":195000,"derivative":{"exercise_price":3.32,"expiration_date":"2035-01-13","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000950170-25-005392","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/949858/000095017025005392/ownership.xml","form_type":"4"}},{"id":1303878,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Performance Restricted Stock Unit (PRSU)","published_at":"2025-01-14T21:42:01.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":455000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones being met.  The PRSUs will lapse in full if achievement of at least one of the milestones is not met."}],"balance_after":455000,"derivative":{"expiration_date":"2029-01-13","underlying":"Common Stock","underlying_shares":455000},"source":{"system":"sec-edgar","filing":"0000950170-25-005392","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000095017025005392/ownership.xml","form_type":"4"}},{"id":1458230,"issuer":{"id":89110,"kind":"organization","name":"TFF Pharmaceuticals, Inc.","symbol":"TFFP"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-07-08T17:40:26.000Z","date":"2024-07-03","kind":"grant","planned":false,"acquired":true,"shares":1583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest in full on June 19, 2025."}],"balance_after":1583,"derivative":{"exercise_price":1.82,"exercise_date":"2025-06-19","expiration_date":"2034-07-03","underlying":"Common stock","underlying_shares":1583},"source":{"system":"sec-edgar","filing":"0001213900-24-059871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1279309/000121390024059871/ownership.xml","form_type":"4"}},{"id":1458229,"issuer":{"id":89110,"kind":"organization","name":"TFF Pharmaceuticals, Inc.","symbol":"TFFP"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-08T17:40:26.000Z","date":"2024-07-03","kind":"grant","planned":false,"acquired":true,"shares":1583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying restricted stock units (\"RSUs\"). Each RSU entitles its holder to receive one share of common stock of the issuer. The RSUs vest and settle in full on June 19, 2025."}],"balance_after":1583,"source":{"system":"sec-edgar","filing":"0001213900-24-059871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279309/000121390024059871/ownership.xml","form_type":"4"}},{"id":1537524,"issuer":{"id":89110,"kind":"organization","name":"TFF Pharmaceuticals, Inc.","symbol":"TFFP"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-04-22T20:53:33.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":3110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were awarded to the Reporting Person in lieu of their quarterly cash director fee for the first quarter of 2024.\n The settlement of the RSUs is contingent on stockholder approval, at the Issuer's 2024 annual meeting of stockholders, or Annual Meeting, of an amendment to increase the share reserve under the Issuer's 2021 Stock Incentive Plan, or 2021 Plan. The RSUs shall terminate if the Issuer's stockholders do not approve the proposed amendment to the 2021 Plan at the Annual Meeting. Subject to stockholder approval of the amendment to the 2021 Plan, and subject further to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were awarded to the Reporting Person in lieu of their quarterly cash director fee for the first quarter of 2024.\n The settlement of the RSUs is contingent on stockholder approval, at the Issuer's 2024 annual meeting of stockholders, or Annual Meeting, of an amendment to increase the share reserve under the Issuer's 2021 Stock Incentive Plan, or 2021 Plan. The RSUs shall terminate if the Issuer's stockholders do not approve the proposed amendment to the 2021 Plan at the Annual Meeting. Subject to stockholder approval of the amendment to the 2021 Plan, and subject further to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing."}],"balance_after":3110,"derivative":{"underlying":"Common stock","underlying_shares":3110},"source":{"system":"sec-edgar","filing":"0001213900-24-035085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279309/000121390024035085/ownership.xml","form_type":"4"}},{"id":1672346,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T00:22:40.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of 18 months from the grant date or the date immediately prior to the Issuer's 2025 annual meeting of stockholders."}],"balance_after":31500,"derivative":{"exercise_price":4.55,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001209191-24-002207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919124002207/doc4.xml","form_type":"4"}},{"id":1709025,"issuer":{"id":89110,"kind":"organization","name":"TFF Pharmaceuticals, Inc.","symbol":"TFFP"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T16:08:25.000Z","date":"2023-12-13","kind":"grant","planned":false,"acquired":true,"shares":132442,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and first become exercisable in 36 equal monthly installments, with the first installment vesting on December 13, 2024 and the remaining installments on the 13th of the month for the next 35 months."}],"balance_after":132442,"derivative":{"exercise_price":0.35,"exercise_date":"2024-12-13","expiration_date":"2033-12-13","underlying":"Common Stock","underlying_shares":132442},"source":{"system":"sec-edgar","filing":"0001213900-23-096082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279309/000121390023096082/ownership.xml","form_type":"4"}},{"id":1861203,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T20:15:36.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were granted on March 29, 2023 (the \"Grant Date\") pursuant to the 2023 Non-Employee Director Equity Incentive Plan (the \"Plan\"), subject to the Plans approval by the Issuers stockholders. The Plan was approved by the Issuers stockholders at the Issuers 2023 Annual Meeting of Stockholders on June 7, 2023. These options will vest on the one month anniversary of the Grant Date and thereafter in monthly installments over 36 months."}],"balance_after":23250,"derivative":{"exercise_price":5.97,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001209191-23-035787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919123035787/doc4.xml","form_type":"4"}},{"id":1862349,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:30:31.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":0.9,"underlying":"Common Stock","underlying_shares":12765},"source":{"system":"sec-edgar","filing":"0000899243-23-014876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014876/doc4.xml","form_type":"4"}},{"id":1862348,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:30:31.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":1.04,"underlying":"Common Stock","underlying_shares":12765},"source":{"system":"sec-edgar","filing":"0000899243-23-014876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014876/doc4.xml","form_type":"4"}},{"id":1862347,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:30:31.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.56,"underlying":"Common Stock","underlying_shares":14893},"source":{"system":"sec-edgar","filing":"0000899243-23-014876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014876/doc4.xml","form_type":"4"}},{"id":1862346,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:30:31.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.46,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-23-014876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014876/doc4.xml","form_type":"4"}},{"id":1862345,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:30:31.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.6,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-014876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014876/doc4.xml","form_type":"4"}},{"id":1862344,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:30:31.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":26.99,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-014876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014876/doc4.xml","form_type":"4"}},{"id":1935206,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-30T15:27:21.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the one month anniversary of March 29, 2023 and thereafter in monthly installments over 36 months."}],"balance_after":24000,"derivative":{"exercise_price":5.97,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-23-021585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919123021585/doc4.xml","form_type":"4"}},{"id":2240207,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-07T17:34:54.000Z","date":"2022-06-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting."}],"balance_after":30000,"derivative":{"exercise_price":3.46,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-22-012468","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761922012468/doc1.xml","form_type":"4"}},{"id":2955267,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-07T18:07:25.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full and become exercisable on the day immediately preceding the 2022 Annual Meeting."}],"balance_after":20000,"derivative":{"exercise_price":4.6,"expiration_date":"2030-12-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-20-020724","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761920020724/doc1.xml","form_type":"4"}},{"id":3109164,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-16T19:24:09.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the  first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":26.99,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-20-012249","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761920012249/doc1.xml","form_type":"4"}},{"id":3254733,"issuer":{"id":151460,"kind":"organization","name":"VIVUS INC","symbol":"VVUS"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2020-02-24T18:06:09.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider."}],"balance_after":15000,"derivative":{"exercise_price":2.41,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001123292-20-000324","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/881524/000112329220000324/edgar.xml","form_type":"4"}},{"id":3781879,"issuer":{"id":151460,"kind":"organization","name":"VIVUS INC","symbol":"VVUS"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2018-10-29T19:49:38.000Z","date":"2018-10-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider."}],"balance_after":15000,"derivative":{"exercise_price":3.53,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001123292-18-001042","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/881524/000112329218001042/edgar.xml","form_type":"4"}},{"id":3889727,"issuer":{"id":151460,"kind":"organization","name":"VIVUS INC","symbol":"VVUS"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-06-19T16:15:40.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The option expires on the earlier of (a) June 15, 2025 or (b) the twelve month anniversary of the date the reporting person ceases to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan)."}],"balance_after":200000,"derivative":{"exercise_price":0.84,"exercise_date":"2018-06-15","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001123292-18-000819","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/881524/000112329218000819/edgar.xml","form_type":"4"}},{"id":4085441,"issuer":{"id":151460,"kind":"organization","name":"VIVUS INC","symbol":"VVUS"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Executive Office"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-30T18:37:37.000Z","date":"2018-01-26","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36) of the total number of shares underlying the option vest on the last day of each month, beginning January 31, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan) on the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option expires on the earlier of (a) January 26, 2025 or (b) the twelve (12) month anniversary of the date the reporting person ceases to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan)."}],"balance_after":600000,"derivative":{"exercise_price":0.46,"underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001123292-18-000244","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/881524/000112329218000244/edgar.xml","form_type":"4"}},{"id":4248846,"issuer":{"id":151460,"kind":"organization","name":"VIVUS INC","symbol":"VVUS"},"owners":[{"id":75701,"kind":"person","name":"KING THOMAS BRAXTON","position":1,"cik":"0001279309","reported_name":"KING THOMAS BRAXTON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-31T20:28:21.000Z","date":"2017-07-27","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One eighteenth (1/18) of the total number of shares underlying the option were fully vested on the date of grant, and one thirty-sixth (1/36) of the total number of shares underlying the option vest on the 24th of each month, beginning on August 24, 2017, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan) on the relevant vesting dates."}],"balance_after":125000,"derivative":{"exercise_price":1.15,"expiration_date":"2024-07-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001123292-17-001329","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/881524/000112329217001329/edgar.xml","form_type":"4"}}]}